

# AstraZeneca

## VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) Reporting

### Overview

In Accordance with the requirements of subsection B set forth in the VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) regulation, this is our 30-day post launch report of the introduction of the products listed below, into the state of Vermont.

### The Product(s)

This is the HUD (Hospital Unit Dose) of the Farxiga 10MG Tab for use in hospitals.

### Marketing Plans

-

### Pricing Plans

When setting the price of medicines AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value.

Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.

Branded Name	Generic Name	NDC	WAC Package Price	Effective Date
FARXIGA TAB 10MG HUD BL 3X10 EA US	dapagliflozin	00310- 6210-39	\$548.83	12/06/2022

### Estimated Volume of Patients

-

### Breakthrough Designation

N/A

**Date of Acquisition**

The date of acquisition of the product(s) is listed below.

<b>NDC</b>	<b>Date of Acquisition</b>
00310-6210-39	N/A